Baseline Patient Characteristics
| No. | 20* |
| Gender | 15 male/5 female |
| Median age (range) | 42 yrs (20 to 54 yr) |
| Diagnosis | |
| Leukemia | 14 |
| Myeloma | 3 |
| Lymphoma | 2 |
| Breast cancer | 1 |
| Donor | |
| Matched sibling | 10 |
| Mismatched related | 1 |
| Matched unrelated | 9 |
| GVHD prophylaxis | |
| FK506-based | 15 |
| CSA-based | 5 |
| Prior GVHD treatment | |
| Corticosteroids | 20 |
| Antithymocyte globulin | 3 |
| Mycophenolate mofetil | 1 |
| Investigational drug | 1 |
| Baseline GVHD grade | |
| 1 | 0 |
| 2 | 5 |
| 3 | 11 |
| 4 | 4 |
| No. | 20* |
| Gender | 15 male/5 female |
| Median age (range) | 42 yrs (20 to 54 yr) |
| Diagnosis | |
| Leukemia | 14 |
| Myeloma | 3 |
| Lymphoma | 2 |
| Breast cancer | 1 |
| Donor | |
| Matched sibling | 10 |
| Mismatched related | 1 |
| Matched unrelated | 9 |
| GVHD prophylaxis | |
| FK506-based | 15 |
| CSA-based | 5 |
| Prior GVHD treatment | |
| Corticosteroids | 20 |
| Antithymocyte globulin | 3 |
| Mycophenolate mofetil | 1 |
| Investigational drug | 1 |
| Baseline GVHD grade | |
| 1 | 0 |
| 2 | 5 |
| 3 | 11 |
| 4 | 4 |
Number of patients unless indicated otherwise.